GT
EGRX

Glenmede Trust’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Glenmede Trust’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-258
Closed -$10K – 2340
2020
Q3 		$10K Buy
258
+170
+193% +$7.44K ﹤0.01% 1894
2020
Q2 		$4K Buy
88
+12
+16% +$599 ﹤0.01% 2148
2020
Q1 		$4K Hold
76
– – ﹤0.01% 2738
2019
Q4 		$4K Hold
76
– – ﹤0.01% 2738
2019
Q3 		$4 Buy
76
+45
+145% +$2.53K ﹤0.01% 2726
2019
Q2 		$1 Hold
31
– – ﹤0.01% 3000
2019
Q1 		$1 Sell
31
-25
-45% -$1.11K ﹤0.01% 2980
2018
Q4 		$2 Buy
+56
New +$2.89K ﹤0.01% 2804

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Glenmede Trust's EGRX Position: Q4 2020 in Review

Glenmede Trust sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 258 shares — an estimated $10K sold.

Glenmede Trust first reported a position in EGRX in Q4 2018 and held it in 8 quarters. The position peaked at $10K in Q3 2020. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Glenmede Trust reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 258 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $10K.
  • Glenmede Trust first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2018 and held it in 8 quarters.
  • Glenmede Trust's Eagle Pharmaceuticals, Inc. position peaked at $10K in Q3 2020.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.